Startupskyron.bio teams up with Servier to test “precision glycosylation” as a new lever for antibody performanceParis-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier. This agreement marks an early proof-of-concept deal designed … more ➔
Molecular Partners AG & NuMeRI, presentation Feb. 2026RadiopharmaceuticalsRadioligands give Molecular Partners new momentum in a market already at full speedThe Zurich-based developer is increasingly focusing its pipeline on radiopharmaceutical cancer therapies. A recent development agreement with isotope specialist Eckert & Ziegler marks another step in … more ➔
BispecificUCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager dealUCB is adding a new kind of immune-cell weapon to its immunology arsenal. The Belgian biopharma said it has struck a global licensing deal with Hong Kong–based Antengene for ATG-201, a CD19/CD3 bispecific … more ➔
LicensingBoehringer steps back from MASH programm as OSE restructure its pipelineFrench biotech OSE Immunotherapeutics is narrowing its ambitions to just two late-stage programs after a one–two hit: AbbVie backing away from an inflammation partnership and Boehringer Ingelheim halting … more ➔
Courtesy Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, GermanyRealtime ImagingNVision visualizes metabolics at work and expands to the Cambridge Innovation ClusterQuantum computers? While most people have heard that their massively parallel data processing could open up an entirely new dimension of information technology, tangible real-world examples remain scarce. … more ➔
Sitryx TherapeuticsImmunologySitryx adds another BigPharma and partners with Boehringer Ingelheim in autoimmune pushOxford-based immunology specialist Sitryx has entered into a new agreement with Boehringer Ingelheim aimed at advancing a novel small-molecule programme in autoimmune and inflammatory disease. The deal … more ➔
M&AJapan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million dealTakeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 … more ➔
Rare diseaseargenx expands VYVGART into ocular MG as profitability signals franchise maturityargenx delivered two significant updates on the same day: positive Phase 3 results in ocular myasthenia gravis (oMG) and its first full year of operating profitability. Together, the announcements show … more ➔
anti-obesityNovo Nordisk partners with MIT spinout Vivtex in deal worth up to $2.1bn to advance oral biologics for obesityDenmark’s Novo Nordisk has signed a collaboration with Boston-based Vivtex Corporation to develop next-generation oral biologic medicines for obesity, diabetes and associated metabolic diseases. Vivtex … more ➔
AcquisitionGSK buys 35Pharma for $950m, targeting next-generation pulmonary hypertension therapy and the TGF-β superfamilyGSK will pay $950m for Montreal-based 35Pharma to secure HS235, an investigational activin signalling inhibitor that has completed Phase I trials in healthy volunteers and is set to begin studies in … more ➔
Molecular Partners AG & NuMeRI, presentation Feb. 2026
Courtesy Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany
Sitryx Therapeutics
